Menu Developing Abuse-Deterrent Medications to Reduce the Potential for Harm Vallon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel abuse-deterrent medications for CNS disorders. Learn More About Us Our Pipeline Prescription Stimulant Abuse is a Large and Growing Concern 5+ million adolescents and adults misuse prescription stimulants annually1 From 2004 – 2011, emergency department visits due to non-medical use of stimulants2 Increased 4.7x From 2010 – 2017, deaths associated with prescription stimulants3 Increased 5x Sources: 1. SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2018; 2. Drug Abuse Warning Network, 2011; 3. Black, CPDD, 2020. Learn More About Stimulant Abuse Our Technology is Designed to Resist Manipulation for Snorting and Provide Barriers to Injection Our lead investigational product candidate, ADAIR (Abuse-Deterrent Amphetamine Immediate-Release), is a proprietary abuse-deterrent formulation of immediate release (IR) dextroamphetamine designed to deter attempts to crush and snort and provides barriers to injection. Our Technologies Vallon News Vallon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update November 12, 2021 Vallon Pharmaceuticals to Present at the Virtual Investor Roundtable Event November 11, 2021 Visit Newsroom Quick Links Corporate PresentationDownload Sign Up for AlertsSubscribe Sign Up for Updates © 2021 Vallon Pharmaceuticals | Terms of Use | Privacy Policy ADAIR is an investigational new drug product and has not yet been approved by the FDA. All trademarks shown are the property of their respective owners.

Menu Investors Subscribe to Receive News Alerts Overview Press Releases Events + Presentations Company Information Stock Information Analyst Coverage SEC Filings Corporate Governance News Alerts Email Address First Name Last Name Company Press Releases All SEC Filings 10-K Filings 10-Q Filings 8-K Filings Proxy Statements Section 16 Filings - End of day Stock Detail - End of day Unsubscribe from all email communications. Sign Up for Updates © 2021 Vallon Pharmaceuticals | Terms of Use | Privacy Policy ADAIR is an investigational new drug product and has not yet been approved by the FDA. All trademarks shown are the property of their respective owners.